Cancer risk! 10 blood pressure temporarily deprived of admission
Valsartan, Irbesartan or Olmesartan, an important active ingredient for the treatment of hypertension and also in many combination products is included.
The reason for the return in 2018, a production-related contamination of the active substance was calls with that N-nitroso dimethyl amine. And this substance is classified by the International Agency for research on cancer of the WHO and the EU as likely to be carcinogenic in humans.
List of medicinal products, for which approvals according to the BfArM, with effect from the 01.03.2020 the Rest was arranged:
- Irbesartan/HCT axcount 150 mg/12.5 mg (axcount generics GmbH)
- Irbesartan/HCT axcount 300 mg/12.5 mg (axcount generics GmbH)
- Irbesartan/HCT axcount 300 mg/25 mg (axcount generics GmbH)
- Valsartan axcount 160 mg (axcount generics GmbH)
- Valsartan axcount 320 mg (axcount generics GmbH)
- Valsartan axcount 40 mg (axcount generics GmbH)
- Valsartan axcount 80 mg (axcount generics GmbH)
- Olmesartanmedoxomil HEC Pharm 10 mg (HEC Pharm GmbH)
- Olmesartanmedoxomil HEC Pharm 20 mg (HEC Pharm GmbH)
- Olmesartanmedoxomil HEC Pharm 40 mg (HEC Pharm GmbH)
According to the BfArM, the marketing authorisation holders have not or not completely implemented risk-minimizing measures as yet.
Virus expert explains when it is Corona-epidemic in Germany would stop
*The Post “Cancer Hazard! 10 blood pressure is temporarily deprived of admission” published by Wizelife. Contact with the executives here.
